Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Qing Zhou,Lin Wu,Pei Hu,Tongtong An, Jianying Zhang,Li Zhang,Xiaoqing Liu,Feng Luo,Xiaohui Zheng,Ying Cheng,Nong Yang,Junling Li,Jifeng Feng,Baohui Han,Yong Song,Kai Wang, J. Fang, Hong Zhao,Yongqian Shu,Xiaoyan Lin, Zhihong Chen,Bin Gan, Weili Xu,Wei Tang, Xiaoying Zhang, Jing Yang,Xin Xu,Yi‐Long Wu

openalex（2023）

Cited 0|Views0
No score
Abstract
Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
More
Translated text
Key words
EGFR Mutations,Adjuvant Therapy
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined